1、Rubicon 14 支撐導管UnderstandingChronic Total Occlusions Clinical Overview看看慢性全閉塞病變的情況CTO-慢性全閉塞性病變臨床需求CTOs在下肢手術中的發病約為30-40%；將近40%的CTO需要多種技術以穿越病變1新技術的發展推動了血管腔內治療的CTO治療2 沒有CTO治療的金標準3 多種治療方案實驗性及錯誤的方法器械選擇決定于熟練程度和使用的便利性主要挑戰產品表現不佳和臨床效果不佳器械外廓大，精確度有限，學習曲線長額外的手術時間和復雜性1. 2010-2011 Global PI Tracking Study; 2. Tru

2、e lumen re-entry devices facilitate subintimal angioplasty and stenting of CTOs Jacobs, D., et al, Journal of Vasc Surgery, Jun 2006 3. PI MAB 2011 FeedbackCTO解剖大部分SFA長段閉塞，通常可以在造影下看到近端像樹樁一樣的頭端，然后遠端血管不同程度顯影，或來自股深動脈的側支。Crossing Peripheral CTOs. Tony S. Das, MD. Endovascular Today, March 2006Results fr

3、om case studies are not predictive of results in other cases. Results in other cases may vary.嚴重肢體缺血(CLI)患者的臨床考量CLI不僅僅只是針對BTKCLI不僅僅是由BTK血管病變引起的，為了重建足部的血運，我們需要考慮整個下肢的血管狀況流入道病變 主要是在SFA，也有在髂動脈. (CLI累及髂動脈少見，如累及髂動脈時多數患者會有嚴重的間歇性跛行)流出道病變 主要是在脛動脈和腓動脈，但通常擴展至足部動脈一個417例患者的研究表明，每位患者在膝關節和足部之間的血管平均有6.9個病灶病灶分布Vasc

4、ular Involvement in Diabetic Subjects with Ischemic Foot Ulcer: A New Morphologic Categorization of Disease SeverityL. Graziani et al. Eur J Vasc Endovasc Surg 33, 453e460 (2007)BTK閉塞最為常見，但SFA的病變更值得關注Lesion Distribution (417 patients, 2893 lesions)無法穿越? 無法治療! 穿刺和穿越病變是最令人沮喪，最耗時的！如果你無法到達和穿越病變，就無法進行治療！

5、RubiconTM 14支撐導管Rubicon 14-產品參數All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with ea

6、ch device. Information for the use only in countries with applicable health authority product registrations.Rubicon 14支撐導管突破強硬病變超低的頭端通過外廓幫助通過復雜病變強硬的遠端頭端和桿身材料提供優秀的推送性三個不透射線標記點提供優秀的可視性0.018” (0.46 mm) 頭端通過外廓新一代尼龍頭端和桿身材料三個不透射線標記點對比明顯的紫色頭端透明接頭和近端桿身材料遠端親水涂層135 cm和150cm長度提高復雜病變進入和通過性加強推送性，提高 病變通過性能優秀的可視性更

7、易辨識，簡化導絲的裝載提高血流回滲的可視性？提高通過性多種長度選擇，適用于近端及遠端病變Rubicon 14支撐導管關鍵特性與利益利益特性 Rubicon 14支撐導管產品定位突破強硬病變Tackle Tougher LesionsRubicon 14支撐導管促進/提高致密或閉塞性病變的通過-Facilitates crossing of tight occlusions.0.018”的頭端通過外廓，強硬的新一代遠側頭端技術提供了優秀的推送能力，加上三個不透射線標記點，使得Rubicon具有卓越的病變通過性為你在應對致密或閉塞病變時提供最大的幫助！CXITM Support Catheter-

8、COOK0.018”及0.035”系統90,135,150cm三種長度可供選擇直頭和彎頭兩種頭端形狀桿身3個，頭端1個，共4個不透射線標記點遠端40cm桿身有親水涂層桿身金屬編織結構價格：RMB5000TrailBlazer Support Catheter-Covidien0.014”,0.018”及0.035”系統65,90,135,150cm工作長度直頭頭端外廓：0.035”系統-0.040”0.018”系統-0.022”0.014”系統-0.019”三個不透射線標記點遠端40cm親水涂層價格：RMB3000+Rubicon 14支撐導管更好的推送性Average measurement

9、s taken by Boston Scientific. N = 10. Data on file. Bench test results may not necessarily be indicative of clinical performance.Push is defined as a measure of the shafts ability to transmit force to distal tip in straight-line configuration. All cited trademarks are the properties of their respective owners. TrailBlazer TM is a registered trademark of ev3. Quick Cross is a product owned by Spectranetics; Minnie is a product owned by Vascular solutions.Rubicon 14支撐導管超低的頭端通